Matthew Walsh
Organon CFO

As Chief Financial Officer, Matt Walsh is responsible for the development and execution of Organon’s financial strategy. He is focused on driving profitability and shareholder value and ensuring the highest standard of financial integrity for Organon so it can reach its vision of becoming a leading women’s health company.

Over his career, Matt has served in several public companies as the CFO and in related roles. Before joining Organon, Matt was the executive vice president and CFO at Allergan and Catalent. Previously, he held finance and leadership positions at Escala Group and GenTek. Matt has also served in corporate development and other roles across the chemical and banking industries.

Matt is a CFA® Charterholder. He serves on the board of Certara, a privately owned provider of software and consulting services to the life sciences industry, and is a former board member of Multicolor Corporation, a label solutions provider.

Matt received a B.S. in chemical engineering and an M.B.A. from Cornell University.

About Organon
Organon is a global healthcare company formed through a spinoff from Merck to focus on improving the health of women. It has a portfolio of more than 60 trusted medicines and products that address an entire spectrum of conditions women face. Led by the growing reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon will pursue opportunities to partner with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast-growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, N.J.